Skip to main content
. Author manuscript; available in PMC: 2024 Mar 29.
Published in final edited form as: Ophthalmology. 2021 Jul 8;128(10):e51–e68. doi: 10.1016/j.ophtha.2021.05.031

Figure 13. Examples of ROP reactivation.

Figure 13.

(A) Image at 38 weeks post-menstrual age (PMA) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection at 32 weeks PMA with vascularization into peripheral avascular retina. Demarcation line (arrow) at the leading edge is reactivated stage 1. (B) Image of left eye at 100 weeks PMA after treatment with intravitreal anti-VEGF injection at 38 weeks PMA. There was vascularization into the peripheral avascular retina. There are often notable vascular abnormalities at the site of the original ridge, and in some cases residual fibrosis (asterisk), which is not indicative of reactivation unless accompanied by increasing vascular activity. (C) Image of vascularization into peripheral avascular retina with reactivated stage 1 disease (arrow) at 68 weeks PMA, after treatment with intravitreal anti-VEGF injection at 37 weeks PMA. Note multiple circumferential vascular loops at the site of the original ridge (asterisk). (D) Reactivation in a right eye at 67 weeks PMA, which had undergone intravitreal anti-VEGF injection at 33 weeks and again at 52 weeks PMA. There is reactivated stage 3 (asterisk) posterior to the leading edge of vascularization (arrow). (E) Left eye with reactivated stage 3 at the leading edge (arrow) at 50 weeks PMA, after intravitreal anti-VEGF injection at 36 weeks PMA. Vascularization into peripheral avascular retina has occurred between the original ridge (asterisks) and anterior reactivation. (F) Fluorescein angiogram at 45 weeks PMA of a left eye that had intravitreal anti-VEGF injection at 34 weeks PMA. There is leakage both at sites of leading edge reactivation (arrow), and at the original border (asterisk). (G) Right eye with zone I disease treated with intravitreal anti-VEGF injection at 34 weeks PMA (left side, arrow), and which appeared regressed on clinical exam at 38 weeks PMA (middle image, arrow). At 51 weeks PMA, the eye developed reactivated stage 3 at the same site (right side, arrow), without evidence of vascularization into peripheral avascular retina.